- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01648244
The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes (CADS)
24. november 2015 opdateret af: Alicia L. Warnock, Walter Reed National Military Medical Center
The Use of a Computer Assisted Diabetes Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes Who Are Treated by Primary Care Providers
The primary purpose of this study is to determine whether the use of CADS by primary care providers (PCPs) for their patients with type 2 diabetes (T2DM) changes the quality of care relative to a "usual care" group in terms of objective outcome measures of glycemic control (e.g., A1c, mean blood glucose, frequency of hypoglycemic episodes) and in terms of subjective ratings by patients.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The CADS software integrates the patient's home blood glucose data with appropriate laboratory data (e.g.
A1c, liver function, kidney function), demographic data (age, gender), current and previous medications, and active/inactive medical diagnoses.
The software makes a recommendation about what medication changes are appropriate with potential alternates.
Providers with their patients are block randomized into CADS or "Usual Care" for 1 year.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
28
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Maryland
-
Bethesda, Maryland, Forenede Stater, 20889
- Walter Reed National Military Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Non-specialist physician (general internist or family practitioner), nurse practitioner, physicians assistant
- Absence of orders for deployment or permanent change of station
- Willingness to recruit up to 19 patients prior to randomization
- Willingness to deliver "usual care" as defined in Section 6.3.2 of the protocol.
Exclusion Criteria:
- Specialist physicians
- Orders for deployment or permanent change of station
- Unwillingness to recruit up to 19 patients prior to randomization
- No prior experience with management of type 2 diabetes in adults
- Unwillingness to deliver "usual care" as defined in Section 6.3.2 of the protocol.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Computer-Assisted Decision Support
These providers will use the CADS program to treat their enrolled patients.
|
The CADS software makes a recommendation about what medication changes are appropriate with potential alternates.
CADS providers will either "accept" or "reject" the recommendation by the software.Providers with their patients are block randomized into CADS or "Usual Care" for 1 year.
Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month.
They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit.
Those getting "usual care" will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in A1c
Tidsramme: baseline, 12, 24, 36, and 48 months
|
Change is A1c will be measured 5 times over the course of the study to compare the patients for whom the provider is using CADS to those patients whose providers are delivering "usual care".
|
baseline, 12, 24, 36, and 48 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Major events
Tidsramme: ongoing
|
The number of major ("severe") hypoglycemic events whether subjective (undocumented) or objective (SMBG or other confirmation, need for intervention, seizure, coma), and emergency room visits for DM-related causes.
|
ongoing
|
|
Other DM-related events
Tidsramme: ongoing
|
Number of ER visits for DM-related causes, DM-related hospitalizations and hospital days, and DM-related clinic visits.
|
ongoing
|
|
Glucose measures
Tidsramme: baseline, 12, 24, 36, 48 months
|
Mean pre-prandial glucose, mean post-prandial glucose, post-prandial glucose excursions
|
baseline, 12, 24, 36, 48 months
|
|
Blood pressure
Tidsramme: baseline, 12, 24, 36, and 48 months
|
Clinically significant or statistically detectable changes in BP
|
baseline, 12, 24, 36, and 48 months
|
|
Lipids
Tidsramme: baseline, 12, 24, 36, and 48 months
|
Clinically significant or statistically detectable changes in lipid profile.
|
baseline, 12, 24, 36, and 48 months
|
|
Patient satisfaction with treatment
Tidsramme: basline and 48 months
|
Clinically significant or statistically detectable changes in satisfaction with treatment as measured by the DTSQ.
|
basline and 48 months
|
|
Quality of life
Tidsramme: baseline and 48 months
|
Clinically significant or statistically detectable changes in quality of life for patients with DM as measured by the SF-8.
|
baseline and 48 months
|
|
Degree of Acceptance
Tidsramme: baseline and 48 months
|
The degree of acceptance of CADS by PCPs as measured by a technical assessment questionnaire.
|
baseline and 48 months
|
|
Acceptance of uploading data
Tidsramme: baseline, 12, 24, 36, and 48 months
|
The degree of acceptance of uploading the glucose meters by patients as measured by a technical assessment questionnaire.
|
baseline, 12, 24, 36, and 48 months
|
|
Demographic variables
Tidsramme: baseline and 48 months
|
The relationship of the primary and/or secondary outcomes to the type of provider, board-certification or eligibility, years in practice, age and gender.
|
baseline and 48 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Robert A Vigersky, M.D., Walter Reed National Military Medical Center
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. marts 2012
Primær færdiggørelse (Faktiske)
1. marts 2015
Studieafslutning (Faktiske)
1. marts 2015
Datoer for studieregistrering
Først indsendt
17. juli 2012
Først indsendt, der opfyldte QC-kriterier
19. juli 2012
Først opslået (Skøn)
24. juli 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
25. november 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. november 2015
Sidst verificeret
1. november 2015
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 353757
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type II diabetes mellitus
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...AfsluttetType II diabetes mellitusTyskland
-
Baqai Institute of Diabetology and EndocrinologyNational Institute for Health Research, United Kingdom; University of York og andre samarbejdspartnereRekrutteringType II diabetes mellitusPakistan
-
HealthInsightCenter for Technology and Aging; VoxivaUkendtType II diabetes mellitusForenede Stater
-
University of Malagaclinical professorIkke rekrutterer endnu
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaAfsluttetDiabetes mellitus type II,Slovenien
-
Laboratorios Silanes S.A. de C.V.RekrutteringDyslipidæmi forbundet med type II diabetes mellitusMexico
-
pico-tesla Magnetic Therapies, LLCAfsluttetType II diabetes mellitusForenede Stater
-
EMSRekrutteringDyslipidæmi forbundet med type II diabetes mellitusBrasilien
-
Daiichi Sankyo, Inc.Daiichi Sankyo Korea Co., Ltd.AfsluttetDyslipidæmi forbundet med type II diabetes mellitusKorea, Republikken
-
Damanhour UniversityTanta UniversityAfsluttetDyslipidæmi forbundet med type II diabetes mellitusEgypten
Kliniske forsøg med Computer-Assisted Decision Support
-
US Department of Veterans AffairsAfsluttet
-
University of CalgaryAlberta Health services; University of Alberta; Covenant HealthAfsluttet
-
University of California, San FranciscoAfsluttetForhøjet blodtryk | Nyreinsufficiens, kroniskForenede Stater
-
Imperial College LondonSanofi; Hospital Universitario La Paz; Hippocrates Research; Axtria, Inc.AfsluttetMyokardieinfarkt | Akut koronarsyndromSpanien, Italien, Det Forenede Kongerige
-
Children's Hospital Medical Center, CincinnatiAfsluttetColitis ulcerosa, pædiatriskForenede Stater
-
Weill Medical College of Cornell UniversityIkke rekrutterer endnuFødselsdepressionForenede Stater
-
Sakarya UniversityThe Scientific and Technological Research Council of TurkeyAfsluttetSmerte | Tilfredshed, patient | Iskiasnerven | Injektionssted | SygeplejerskerKalkun
-
Abdul Latif Jameel Poverty Action LabMassachusetts Institute of Technology; Aurora Health Care; Laura and John...AfsluttetCT-, MR-, NM- og PET-billedordrerForenede Stater
-
University of Colorado, DenverAktiv, ikke rekrutterendeHjertefejl | Beslutningsstøttesystemer, kliniskForenede Stater
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)Ikke rekrutterer endnuHjertefejl | Palliativ plejeForenede Stater